Session Information
Date: Tuesday, November 10, 2026
Title: (2519-2539) Patient Outcomes, Preferences, & Attitudes Poster C
Session Type: Poster Session C
Session Time: 10:30AM-12:30PM
Background/Purpose: A posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the Type 1/Type 2 model. Type 1 manifestations represent classic signs and symptoms of SLE, link to immune-mediated inflammatory pathways, and generally respond to immunosuppressive therapy; type 2 manifestations represent symptoms such as fatigue, widespread pain, cognitive dysfunction, and depressive symptoms that do not respond to the same treatments and represent an area of major unmet need. Type 2 symptoms may be most effectively addressed through non-pharmacologic interventions, yet use of complementary and integrative health (CIH) modalities among people with SLE is understudied. This study characterized the prevalence of CIH usage and its associations with patient-reported outcomes (PROs), including Type 2 symptoms.
Methods:
We used data from the California Lupus Epidemiology Study (CLUES), a prospective population-based cohort of individuals with SLE in the San Francisco Bay Area with annual data collection. PROs measured at year 5 included: PROMIS Pain Interference 4a, PROMIS Fatigue 4a, patient-reported disease activity (via SLE Disease Activity Questionnaire [SLAQ]), and depressive symptoms (via Patient Health Questionnaire [PHQ-8]). In the CLUES Year 6 interviews, we queried participant use of CIH providers (e.g., acupuncturist, homeopath, nutritionist) and CIH modalities (e.g., nutrition, mind-body exercise, supplement usage). Primary analyses comprised two multivariable logistic regression models with PROs as predictors and CIH usage, defined as either having visited a CIH provider or used a CIH modality: (1) cross-sectional and (2) time-lagged with PROs modeled at the preceding annual data collection. Analyses were adjusted for age, sex, race and ethnicity, educational attainment, disease duration, and cardiovascular disease.
Results: The sample (n=251) was 91% female, 33% white, 30% Asian, 26% Hispanic, and 9% African American; mean age 50 (± 14) years; 68% with a college degree; mean disease duration 23 (± 11) years; and 13% on glucocorticoid therapy with ≥ 7.5 mg/day prednisone equivalent. Prevalence of visiting any CIH provider was 11% (n=27) (Figure 1a), using at least one CIH modality was 47% (n=119) (Figure 1b), and any CIH use (provider and/or modality) was 49% (n=124). In the multivariable cross-sectional analysis, all 4 PROs associated with increased odds of CIH use (Table 1). In the time lagged analysis, greater pain interference, patient-reported disease activity, and depressive symptoms at T5 associated with higher odds of using CIH at T6, even after adjusting for covariates (Table 2).
Conclusion: Among a diverse SLE cohort, CIH use was common, with many participants reporting use of at least one CIH modality. Both cross-sectional and time-lagged analyses demonstrated significant associations between worse Type 2 symptoms, which are highly relevant to the experience of living with SLE, and higher odds of using CIH. Findings suggest strong interest in CIH among patients with SLE and support further investigation into the potential role of CIH interventions to addressing key dimensions of impaired quality of life among people with SLE.
Figure 1. Frequency of Using Complementary and Integrative Health (CIH) Among Lupus Patients (Figure 1a: n=27; Figure 1b n=119)
Table 1. Cross-sectional Multivariable Logistic Regression for Association of Type 2 SLE Manifestations with Odds of CIH Use (n = 250)
Table 2. Time-lagged Multivariable Logistic Regression for Association of Type 2 SLE Manifestations at T5 with Odds of CIH Use at T6 (n = 218)
To cite this abstract in AMA style:
Leung J, Park J, Hartogensis W, Katz P, Patterson S. Do Type II Symptoms Predict Complementary and Integrative Health Usage Among People Living with Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/do-type-ii-symptoms-predict-complementary-and-integrative-health-usage-among-people-living-with-systemic-lupus-erythematosus/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-type-ii-symptoms-predict-complementary-and-integrative-health-usage-among-people-living-with-systemic-lupus-erythematosus/
